Clorox (NYSE:CLX – Get Free Report) had its target price lowered by equities researchers at Citigroup from $110.00 to $97.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target would indicate a potential upside of 11.39% from the stock’s current price.
A number of other research analysts also recently issued reports on CLX. Morgan Stanley reduced their price objective on shares of Clorox from $110.00 to $97.00 and set an “equal weight” rating on the stock in a research report on Friday. Barclays set a $85.00 target price on shares of Clorox in a report on Friday. Wall Street Zen upgraded shares of Clorox from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. The Goldman Sachs Group restated a “sell” rating and set a $83.00 target price on shares of Clorox in a report on Friday. Finally, TD Cowen boosted their target price on shares of Clorox from $98.00 to $111.00 and gave the company a “hold” rating in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Clorox has a consensus rating of “Reduce” and a consensus price target of $104.93.
Read Our Latest Stock Analysis on CLX
Clorox Trading Down 9.7%
Clorox (NYSE:CLX – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.09. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.67 billion. Clorox had a net margin of 11.17% and a return on equity of 383.01%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 EPS. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. On average, analysts anticipate that Clorox will post 5.87 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Clorox
Hedge funds have recently bought and sold shares of the company. Haverford Trust Co grew its position in Clorox by 2.8% during the fourth quarter. Haverford Trust Co now owns 3,070 shares of the company’s stock worth $310,000 after buying an additional 84 shares in the last quarter. Field & Main Bank grew its position in Clorox by 3.3% during the fourth quarter. Field & Main Bank now owns 3,100 shares of the company’s stock worth $313,000 after buying an additional 100 shares in the last quarter. Golden State Wealth Management LLC grew its position in Clorox by 28.2% during the fourth quarter. Golden State Wealth Management LLC now owns 454 shares of the company’s stock worth $46,000 after buying an additional 100 shares in the last quarter. Fisher Asset Management LLC grew its position in Clorox by 1.7% during the third quarter. Fisher Asset Management LLC now owns 6,053 shares of the company’s stock worth $746,000 after buying an additional 102 shares in the last quarter. Finally, Kestra Private Wealth Services LLC grew its position in Clorox by 1.8% during the first quarter. Kestra Private Wealth Services LLC now owns 5,957 shares of the company’s stock worth $617,000 after buying an additional 104 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.
Key Clorox News
Here are the key news stories impacting Clorox this week:
- Positive Sentiment: Q3 EPS beat driven by cost savings — Clorox reported higher-than-expected non-GAAP EPS as lower spending and margin actions offset flat sales, showing near-term profitability improvement. CLX Q3 Earnings Beat
- Positive Sentiment: Management emphasizes strategic initiatives — management highlighted innovation and targeted M&A as levers to drive growth beyond cost actions, which could support medium‑term recovery if execution succeeds. Earnings Call Highlights
- Neutral Sentiment: Top-line is weak/flat — revenue was essentially flat year-over-year and roughly in line with estimates, leaving limited organic growth visibility and increasing reliance on cost saves and M&A. Q3 Results & Transcript
- Negative Sentiment: Full-year outlook trimmed — Clorox lowered FY26 EPS guidance (below consensus) and cut sales expectations (reports noted a ~-6% sales outlook), a primary catalyst for the downturn as it signals near-term demand pressure and margin headwinds. Reduced FY26 Outlook
- Negative Sentiment: Analysts cut targets & ratings — Several firms trimmed price targets and adjusted ratings (e.g., Morgan Stanley, Wells Fargo, JPMorgan lowered PTs and/or moved to equal-weight/underweight), amplifying selling pressure and lowering near-term sentiment. Morgan Stanley PT Cut JPMorgan / Wells Fargo Notes
About Clorox
The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.
Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.
Recommended Stories
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
